Hims & Hers Health continues to eye personalized services and global expansion. Read more on what investors should know about ...

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

China has approved a new weight-loss drug that is poised to rival Novo Nordisk and Eli Lilly's popular GLP-1 treatments, ...

The majority (over 9.4 million shares) will go to the Gates Foundation. An additional 943,384 shares are being donated to the ...

With the recent approval in China of Innovent Biologics' (OTCPK:IVBIY) mazdutide as the first-ever dual GLP-1/glucagon ...

These popular medications are now at the center of a major weight loss drug lawsuit. Find out which drugs and involved and ...

When it comes to weight loss, providers and patients argue that GLP-1 medications are not a one-for-one swap and that ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

Novo Nordisk has doubled down on position in the sickle cell disease (SCD) category with a $1.1 billion agreement to acquire Forma Therapeutics, and its therapeutic candidate etavopivat, in phase ...

COPENHAGEN (Reuters) -Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared ...

Spain has partnered with the World Bank to help countries free up money to spend on sustainable development projects via debt ...